Jefferies Initiates Hemab Buy
Jefferies starts coverage of Hemab Therapeutics with a buy rating due to its potential in treating rare bleeding disorders. This move may impact the stock's performance.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.